End-of-Life Care

Introduction to Managing Respiratory Secretions

The management of respiratory secretions is a crucial aspect of end-of-life care, with various medications and interventions available to alleviate symptoms, as recommended by the National Comprehensive Cancer Network, the American College of Chest Physicians, and the American Thoracic Society 1, 2, 3.

Glycopyrrolate is recommended as a first-line treatment for managing respiratory secretions, including sialorrhea (drooling) in patients with neuromuscular disorders, with significant improvement in drooling in 95% of cases in patients with cerebral palsy, as supported by the American College of Chest Physicians, the American Thoracic Society, the National Comprehensive Cancer Network, and the American College of Physicians 1, 2, 3, 4.
The initial dose of glycopyrrolate is 0.2 mg orally TID, and for patients with neuromuscular disorders, starting at a lower dose (0.02 mg/kg) and titrating up, due to its quaternary ammonium anticholinergic mechanism that blocks muscarinic receptors, as recommended by the American College of Chest Physicians 1.

Glycopyrrolate can be administered via various routes, including intramuscular (IM), intravenous (IV), and subcutaneous (SQ), with IV administration being significantly more effective at reducing oral and gastric secretions compared to oral administration, and reassessment of effectiveness should be done after 4 hours 5, 2, 1.
The patient should be positioned with head slightly elevated to help secretion drainage, as suggested by medical guidelines 4.
Monitoring for common adverse effects, including dry mouth, constipation, urinary retention, blurred vision, tachycardia, and behavioral changes, is recommended, as suggested by the National Comprehensive Cancer Network 4, 1, 2.

Alternative medications, such as atropine and scopolamine, can be used with dosing options including subcutaneous administration of 0.4 mg SC q4h PRN for immediate effect, and transdermal patches or 1% ophthalmic solution, 1-2 drops SL q4h PRN, respectively 6, 2, 3.
Scopolamine is useful for increased oral secretions, with a dosing of 0.4 mg SC q4h PRN or transdermal patch (1.5-3 mg) q72h, as recommended by the World Journal of Emergency Surgery 6.
Glycopyrrolate should be used with caution in patients with glaucoma, prostatic hypertrophy, bladder neck obstruction, gastrointestinal obstructive disorders, and severe ulcerative colitis, as recommended by the American Urological Association, the American Gastroenterological Association, and the National Comprehensive Cancer Network 4, 2.

The recommended nebulized dose for children with excessive tracheobronchial secretions is 0.25 mg for those under 12 years and 0.5 mg for those 12 and older, according to the American Academy of Pediatrics 7.
The recommended pediatric dosing of glycopyrrolate is 0.004 mg/kg IV, not to exceed 0.1 mg in a single dose, as recommended by the American Academy of Pediatrics 4.
Glycopyrrolate can be combined with other medications, such as opioids, for comprehensive symptom management, as suggested by the American College of Critical Care Medicine 8.
The combination of glycopyrrolate with intranasal corticosteroids may be more effective than either alone for rhinorrhea, with intranasal ipratropium bromide (0.03% or 0.06%) being specifically effective, as recommended by the Journal of Allergy and Clinical Immunology 9.

The National Comprehensive Cancer Network recommends glycopyrrolate for the management of malignant bowel obstruction (alongside octreotide) and as first-line treatment for managing end-of-life respiratory secretions, with a strong recommendation based on high-quality evidence 3, 2.
The American Thoracic Society, the National Comprehensive Cancer Network, and the American College of Physicians recommend glycopyrrolate as a first-line treatment for managing respiratory secretions, including sialorrhea (drooling) in patients with neuromuscular disorders, with a strong recommendation based on high-quality evidence 1, 2, 3, 4.